Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular (CV) Risk Clear all
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 3 Interventional

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

NCT01516541
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions
Background care, Placebo, dalcetrapib
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
2,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
121
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 112 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 3 Interventional

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

NCT05918861
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
186
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

Circadian Mechanisms, Glucose, and CV Risks in T1D

NCT06624046
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Sleep stability intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Better Adherence to Therapeutic Lifestyle Change Efforts Trial

NCT00458874
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
CIMT results
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 2 Interventional

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

NCT07223385
View directory record Official record
Conditions
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
Interventions
Cardio-Oncology Referral, Notification to PCP/General Cardiologist
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

NCT07088718
View directory record Official record
Conditions
Type 2 Diabetes, Major Adverse Cardiac Events, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
44,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Not applicable Interventional

Gene - Exercise Research Study

NCT00976742
View directory record Official record
Conditions
Cardiovascular Disease Risk Factors
Interventions
Endurance exercise training
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
50 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
332
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 266 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

NCT07166822
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Exercise
Interventions
Experimental group using BumptUp mobile exercise app
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

NCT02525939
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
6,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
122
States / cities
Alexander City, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise & Diet Effects on CV Risk in Firefighters

NCT03344198
View directory record Official record
Conditions
Cardiovascular Risk Factor, Blood Pressure, Exercise, Diet Modification, Health Promotion
Interventions
Circuit Training exercise & Modified Mediterranean diet
Behavioral
Lead sponsor
University of New Hampshire
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Not applicable Interventional

CV CARE: CardioVascular Care in PC Patients

NCT06202820
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Diseases
Interventions
CV Care Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting No phase listed Observational

The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

NCT07284082
View directory record Official record
Conditions
HIV, Menopause, Cardiovascular (CV) Risk, Carotid Arteriosclerosis, Body Composition
Interventions
Whole body MRI
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational

Feasibility, Acceptability, and Validation of a User-friendly Diet Quality Tool in Adults From Ambulatory Nutrition Clinics

NCT07109011
View directory record Official record
Conditions
Weight Management, Cardiovascular (CV) Risk, Metabolic and Nutritional Disorders
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women

NCT04014348
View directory record Official record
Conditions
Cardiovascular (CV) Risk
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years to 45 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

NCT02560805
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Procedure · Behavioral · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Suspended Not applicable Interventional

Weight Management After Cancer for Survivors in Rural Communities

NCT07426952
View directory record Official record
Conditions
Breast Cancer Survivorship, Weight Management, Cardiovascular (CV) Risk, Breast Cancer
Interventions
WeCan-Rural Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
3
States / cities
Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated Phase 3 Interventional

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

NCT00134264
View directory record Official record
Conditions
Coronary Disease, Diabetes Mellitus
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 75 Years
Enrollment
15,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
95
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gilbert, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Jul 21, 2026, 7:27 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846
View directory record Official record
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Jul 21, 2026, 7:27 PM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

NCT07096063
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
Interventions
Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
887,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 21, 2026, 7:27 PM EDT
Completed No phase listed Observational

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

NCT00681759
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2008 · Synced Jul 21, 2026, 7:27 PM EDT